Download Start Form
Patients HCP
This site is for US Health Care Professionals only.

C5i-experienced (eculizumab or ravulizumab) and complement inhibitor–naive patients can share common challenges of PNH

See FABHALTA outcomes in actual patients with PNH

Meet them

Explore different FABHALTA patient types

Patients currently on C5is

Image of a man, portrayal of a patient currently on a C5i

These patients may1-4:

  • Have below-normal Hb levels (<12 g/dL for women or <13 g/dL for men)*
  • Be looking for an option other than infusions
  • Require ≥1 RBC transfusion per year
  • Have elevated ARC
  • Experience fatigue

*Normal Hb levels vary but generally are 12-16 g/dL for women and 13-18 g/dL for men.1

Newly diagnosed patients or those not on a complement inhibitor

Image of a woman, newly diagnosed patient portrayal

These patients may4-6:

  • Have an Hb level <10 g/dL
  • Require ≥1 RBC transfusion per year
  • Have elevated ARC and/or LDH levels
  • Experience fatigue

What are some of the challenges your patients with PNH experience?

 

Experience real patient journeys with FABHALTA

These are real people living with PNH and taking FABHALTA. Discover their stories and see how their experiences may be similar to those of your patients.

Meet Kim, a C5i-experienced patient now taking FABHALTA

Meet Kim

A C5i-experienced patient now taking FABHALTA

Visit profile
Meet Shonda, a C5i-experienced patient now taking FABHALTA

Meet Shonda

A C5i-experienced patient now taking FABHALTA

Visit profile

See the efficacy results for FABHALTA

Explore efficacy

Explore the safety profile for FABHALTA

View safety info

See how adult patients take FABHALTA

Discover oral dosing

Definitions
ARC, absolute reticulocyte count; C5i, C5 inhibitor; Hb, hemoglobin; LDH, lactate dehydrogenase; PNH, paroxysmal nocturnal hemoglobinuria; RBC, red blood cell.

References
1. Cappellini MD, Motta I. Anemia in clinical practice—definition and classification: does hemoglobin change with aging? Semin Hematol. 2015;52(4):261-269. doi:10.1053/j.seminhematol.2015.07.006
2. Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101(2):251-263. doi:10.1007/s00277-021-04715-5
3. Peipert JD, Kulasekararaj AG, Gaya A, et al. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One. 2020;15(9):e0237497. doi:10.1371/journal.pone.0237497
4. Shammo J, Gajra A, Patel Y, et al. Low rate of clinically evident extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with a complement C5i: results from a large, multicenter, US real-world study. J Blood Med. 2022;13:425-437. doi:10.2147/JBM.S361863
5. Kulasekararaj AG, Griffin M, Langemeijer S, et al. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. Eur J Haematol. 2022;109(3):205-214. doi:10.1111/ejh.13783
6. Schrezenmeier H, Roth A, Araten DJ, et al. Baseline characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. 2020;99(7):1505-1514. doi:10.1007/s00277-020-04052-z